Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) Return on equity
Boston Scientific Corporation's return on equity over the twelve months to 30 June 2026 was 15.4%, up 2.9 percentage points from fiscal 2025 (12.5%). Over the past ten years it has ranged from −3.74% (fiscal 2015) to 41.6% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −15.3% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 12.5% | 3.55 |
| FY2024 | 8.92% | 0.46 |
| FY2023 | 8.46% | 4.71 |
| FY2022 | 3.75% | (2.42) |
| FY2021 | 6.17% | 6.96 |
| FY2020 | −0.79% | (42.38) |
| FY2019 | 41.6% | 20.35 |
| FY2018 | 21.2% | 19.73 |
| FY2017 | 1.51% | (3.81) |
| FY2016 | 5.32% | 9.06 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. compare | 38.5% |
| GEHC GE HealthCare Technologies Inc. compare | 19.2% |
| SYK Stryker Corporation compare | 16.5% |
| BSX Boston Scientific Corporation | 15.4% |
| STE STERIS plc compare | 11.4% |
| ABT Abbott Laboratories compare | 10.6% |
| MDT Medtronic PLC compare | 10.6% |
| PHG Koninklijke Philips N.V. compare | 10.2% |
| EW Edwards Lifesciences Corporation compare | 9.42% |
| Medical Devices industry median | −15.3% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement